Report Overview

A concerning surge in the prevalence of anaphylaxis and various other chronic illnesses, such as rheumatoid arthritis, across the country and favorable characteristics of autoinjectors are expected to drive the growth of United States Autoinjectors Market during the forecast period between 2023 and 2029.

United States Autoinjectors Market - Industry Trends & Forecast Report, 2029

United States autoinjector market size was estimated to be worth USD 16.98 billion in 2022. During the forecast period between 2023 and 2029, the United States autoinjector market size is projected to grow at a CAGR of 18.70% reaching a value of USD 56.04 billion by 2029. The flourishing growth of the United States autoinjector market is attributed to the concerning surge in the prevalence of anaphylaxis and various other chronic illnesses such as rheumatoid arthritis and convenience in the use of autoinjectors. Patients can easily use autoinjectors at their homes and self-administer their drug intake. Furthermore, favorable government policies and coverage under Medicare and Medicaid are also proving favorable for the United States autoinjector market growth.

United States Autoinjectors Market – Overview

An autoinjector, sometimes known as an auto-injector, is a piece of medical equipment used to administer a dosage of a specific medicine. Autoinjectors are used to self-administer epinephrine to treat anaphylaxis, to ease migraine patients' urgent discomfort, and for other medical and emergency treatments. The majority of autoinjectors are disposable, spring-loaded, single-use syringes (prefilled syringes). Autoinjectors are created to be simple to use and to be administered by patients themselves or by unskilled persons. Depending on the substance loaded, the injection location may vary, however, it is commonly delivered into the buttocks or thigh.

United States Autoinjectors Market

Growth Drivers

Increasing Prevalence of Allergies in the United States

According to a report published on Medical News, the United States is witnessing a surge of multi-food allergies among children and adults. Food allergy (FA) has developed into a chronic illness in the United States, because of its rising frequency and lasting psychological and physical repercussions in the recent decades. According to a recent study, immunoglobulin E (IgE)-mediated FA affects roughly 10.8% of adults and 7.6% of children in the US. During an emergency, adrenaline autoinjectors are used to treat severe allergic responses (anaphylaxis). They may be administered by anybody, including those who lack medical training and are made to provide a single, set amount of adrenaline. The increasing burden of allergies may emerge as a major driving factor for the United States autoinjectors market.

Restraints

Cross Compatibility Issues with Autoinjector Devices

Autoinjectors are highly convenient to use, especially for patients in home care settings. However, there have been several reports of safety-related problems with auto-injectors and pen injectors, due to usability limitations. A recent notice issued by the FDA stated that the ‘FDA-approved glatiramer acetate injectable medicine items may not all be compatible with autoinjector devices that are optional for use with the medication. The FDA has been informed of instances of missing and incomplete doses as a result of utilizing an autoinjector that is incompatible with the patient's particular glatiramer acetate injectable medication product.’ It may limit the use of autoinjectors, affecting the market growth in the United States.

Impact of COVID-19 on the United States Autoinjectors Market

COVID-19 had a positive impact on the United States autoinjector market in the long term. As the number of COVID-19 patients spiked in the hospitals and the entire healthcare system was overburdened, the patients suffering from other ailments delayed their hospital visits to prevent virus contraction. As a result, the use of autoinjectors in homecare settings to keep medical conditions under check surged, propelling the demand for autoinjectors. With an expanding demand for various medical supplies including autoinjectors, syringes, and thermometers, the manufacturers significantly invested in expanding their production capacity. It is projected to boost the growth of the United States autoinjectors during the post-pandemic period.

United States Autoinjectors Market

Segmental Coverage

United States Autoinjectors Market – By Type

Based on type, the United States autoinjector market is segregated into disposable autoinjectors and reusable autoinjectors segments. The disposable autoinjectors segment accounts for a higher share of the market. It is also projected to register a high growth rate during the forecast period as well. Disposable autoinjectors are most preferred in homecare settings as well as in hospitals because of their ease of use. They also have a higher chance of prevention from cross-contamination and infection.

United States Autoinjectors Market – By Therapy

Based on therapy, the United States autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies. The anaphylaxis therapy segment accounts for the highest share in the United States autoinjector market owing to its high prevalence in the United States. According to the data released by the Asthma and Allergy Foundation of America, it was discovered that anaphylaxis, a potentially fatal allergic response, occurs often in the US. One in fifty Americans experiences it. Many people think that the rate is greater. Most likely, it is closer to one in twenty.

United States Autoinjectors Market – By Root of Administration

Based on the root of administration, the United States autoinjectors market is segmented into subcutaneous and intramuscular. The subcutaneous autoinjectors segment holds a higher share of the market. The subcutaneous auto-injection is given in the fatty tissue, just under the skin, and is generally used by diabetic patients. The high prevalence of diabetes in the United States acts as a major factor for the increasing demand for subcutaneous autoinjectors in the country. However, the intramuscular autoinjectors are projected to register growth at a higher CAGR during the forecast period as they are absorbed faster than subcutaneous injections.

United States Autoinjectors Market – By End User

Based on end users, the United States autoinjectors market is segmented into home care settings, hospitals & clinics, ambulatory surgical centers, and others. The homecare settings segment accounts for the highest share in the United States autoinjectors market. As autoinjectors are designed to be easily used by untrained personnel anywhere. Therefore, they are increasingly being used by geriatric patients in home care settings. Due to the rising number of people visiting hospitals for the treatment of anaphylaxis and other medical disorders, the hospital segment is also predicted to have significant growth over the forecast period.

Competitive Landscape

Competition in the United States autoinjectors market is intense. Prominent players in the market include Mylan N.V., Pfizer Inc., Sanofi, Boehringer Ingelheim International GmbH, Novartis Ag, AbbVie Inc., Amgen Inc., Biogen, Merck & Co., Inc, and Teva Pharmaceuticals Industries Ltd. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

• In August 2022 – Rafa Laboratories Ltd., an Israel-based pharmaceutical company, received approval from the FDA for its 10 mg midazolam autoinjector for the treatment of status epilepticus in adults.

Scope of the Report

By Type

• Disposable Autoinjectors

• Reusable Autoinjectors

By Therapy

• Rheumatoid Arthritis

• Multiple Sclerosis

• Diabetes

• Anaphylaxis

• Other Therapies

By Route of Administration

• Subcutaneous

• Intramuscular

By End User

• Home Care Settings

• Hospitals & Clinics

• Ambulatory Surgical Centers

• Others